JP6992960B2 - キナーゼ阻害剤の用途 - Google Patents

キナーゼ阻害剤の用途 Download PDF

Info

Publication number
JP6992960B2
JP6992960B2 JP2016536145A JP2016536145A JP6992960B2 JP 6992960 B2 JP6992960 B2 JP 6992960B2 JP 2016536145 A JP2016536145 A JP 2016536145A JP 2016536145 A JP2016536145 A JP 2016536145A JP 6992960 B2 JP6992960 B2 JP 6992960B2
Authority
JP
Japan
Prior art keywords
benzo
compound
kinase
pyridazine
kinases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016536145A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016539138A (ja
JP2016539138A5 (enExample
Inventor
ロバート ミックレム，デビッド
Original Assignee
ベルゲンビオ アーエスアー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201321227A external-priority patent/GB201321227D0/en
Priority claimed from GB201323021A external-priority patent/GB201323021D0/en
Application filed by ベルゲンビオ アーエスアー filed Critical ベルゲンビオ アーエスアー
Publication of JP2016539138A publication Critical patent/JP2016539138A/ja
Publication of JP2016539138A5 publication Critical patent/JP2016539138A5/ja
Application granted granted Critical
Publication of JP6992960B2 publication Critical patent/JP6992960B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2016536145A 2013-12-02 2014-11-28 キナーゼ阻害剤の用途 Expired - Fee Related JP6992960B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1321227.9 2013-12-02
GB201321227A GB201321227D0 (en) 2013-12-02 2013-12-02 Use of kinase inhibitors
GB1323021.4 2013-12-24
GB201323021A GB201323021D0 (en) 2013-12-24 2013-12-24 Use of kinase inhibitors
PCT/GB2014/053548 WO2015082887A2 (en) 2013-12-02 2014-11-28 Use of kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020080908A Division JP2020128402A (ja) 2013-12-02 2020-05-01 キナーゼ阻害剤の用途

Publications (3)

Publication Number Publication Date
JP2016539138A JP2016539138A (ja) 2016-12-15
JP2016539138A5 JP2016539138A5 (enExample) 2017-12-28
JP6992960B2 true JP6992960B2 (ja) 2022-02-03

Family

ID=52016110

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016536145A Expired - Fee Related JP6992960B2 (ja) 2013-12-02 2014-11-28 キナーゼ阻害剤の用途
JP2020080908A Pending JP2020128402A (ja) 2013-12-02 2020-05-01 キナーゼ阻害剤の用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020080908A Pending JP2020128402A (ja) 2013-12-02 2020-05-01 キナーゼ阻害剤の用途

Country Status (4)

Country Link
US (1) US9801880B2 (enExample)
EP (1) EP3076966A2 (enExample)
JP (2) JP6992960B2 (enExample)
WO (1) WO2015082887A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE044025T2 (hu) 2010-05-20 2019-09-30 Array Biopharma Inc Makrociklusos vegyületek mint TRK-kináz inhibitorok
ES2857081T3 (es) 2015-07-16 2021-09-28 Array Biopharma Inc Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
ES2948194T3 (es) 2017-01-18 2023-09-01 Array Biopharma Inc Compuestos de pirazolo[1,5-a]pirazina sustituida como inhibidores de la cinasa RET
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
CA3087578C (en) 2018-01-18 2023-08-08 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
US11603374B2 (en) 2018-01-18 2023-03-14 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
TW201932464A (zh) 2018-01-18 2019-08-16 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑基[4,3-c]吡啶化合物
EP3849986B1 (en) 2018-09-10 2022-06-08 Array Biopharma, Inc. Fused heterocyclic compounds as ret kinase inhibitors
EP3873608A1 (en) 2018-10-31 2021-09-08 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
EP4371987B9 (en) 2018-10-31 2025-11-26 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
CN115504967A (zh) * 2021-06-23 2022-12-23 南京正大天晴制药有限公司 作为axl抑制剂的1,2,4-三唑化合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010517412A (ja) 2007-06-21 2010-05-20 エルジー エレクトロニクス インコーポレイティド 直交周波数分割多重化システムで制御チャネルを受信する方法
JP2011522212A (ja) 2007-10-19 2011-07-28 セル・シグナリング・テクノロジー・インコーポレイテツド 癌の分類および使用法
JP2012515225A (ja) 2009-01-16 2012-07-05 ライジェル ファーマシューティカルズ， インコーポレイテッド 転移性癌の予防、治療、または管理のための併用療法に用いるためのａｘｌ阻害薬

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1483400A4 (en) * 2002-02-12 2007-07-11 Quark Biotech Inc USE OF THE AXL RECEPTOR FOR THE DIAGNOSIS AND TREATMENT OF A KIDNEY DISEASE
EP1673399B1 (en) * 2003-08-11 2017-04-05 Monogram BioSciences, Inc. Detecting and profiling molecular complexes
PL1686997T3 (pl) * 2003-11-18 2009-09-30 Novartis Ag Inhibitory zmutowanej formy KIT
PL2078010T3 (pl) * 2006-12-29 2014-07-31 Rigel Pharmaceuticals Inc Triazole podstawione policyklicznym heteroarylem użyteczne jako inhibitory Axl
JP5908728B2 (ja) * 2009-01-06 2016-04-26 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド ピリミド−ジアゼピノンキナーゼ骨格化合物及び疾患を治療する方法
US9050341B2 (en) * 2009-07-14 2015-06-09 Natco Pharma Limited Methods of treating drug resistant and other tumors by administering 6,7-dialkoxy quinazoline derivatives
US8603740B2 (en) * 2010-12-29 2013-12-10 Quest Diagnostics Investments Incorporated BCR-ABL1 splice variants and uses thereof
WO2012143143A1 (en) * 2011-04-21 2012-10-26 Origenis Gmbh Heterocyclic compounds as kinase inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010517412A (ja) 2007-06-21 2010-05-20 エルジー エレクトロニクス インコーポレイティド 直交周波数分割多重化システムで制御チャネルを受信する方法
JP2011522212A (ja) 2007-10-19 2011-07-28 セル・シグナリング・テクノロジー・インコーポレイテツド 癌の分類および使用法
JP2012515225A (ja) 2009-01-16 2012-07-05 ライジェル ファーマシューティカルズ， インコーポレイテッド 転移性癌の予防、治療、または管理のための併用療法に用いるためのａｘｌ阻害薬

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
Ｂｉｏｃｈｉｍｉｃａ ｅｔ Ｂｉｏｐｈｙｓｉｃａ Ａｃｔａ １８３２，２０１３年，ｐ．８９７－９０４
Ｂｌｏｏｄ，２００２年，Ｖｏｌ．９９，Ｉｓｓｕｅ．１ｐ．３８１－３８３
Ｂｌｏｏｄ，２０１１年，Ｖｏｌ．１１７，Ｉｓｓｕｅ．６，ｐ．１９２８－１９３７
Ｂｌｏｏｄ，２０１１年，Ｖｏｌ．１１８，Ｉｓｓｕｅ．２１，ｐ．４２１
Ｂｌｏｏｄ，２０１３年，Ｖｏｌ．１２２，Ｉｓｓｕｅ．２１，ｐ．１４６９
Ｃａｎｃｅｒ Ｒｅｓｅａｒｃｈ，２０１０年，Ｖｏｌ．７０，Ｎｏ．４，ｐ．１５４４－１５５４
Ｄｉｓｅａｓｅ Ｍａｒｋｅｒｓ，２０１９年，Ｖｏｌ．２０１９，Ａｒｔｉｃｌｅ ＩＤ ２３０４９３１，ｐ．１－１５
Ｍｏｌｅｃｕｌａｒ Ｃａｎｃｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，２０１１年，Ｖｏｌ．１０， Ｎｏ．１０，ｐ．１７６３－１７７３
Ｎａｔｕｒｅ Ｍｅｄｉｃｉｎｅ，２０１３年，Ｖｏｌ．１８，Ｎｏ．７，ｐ．１０２８－１０４０

Also Published As

Publication number Publication date
WO2015082887A3 (en) 2015-07-30
WO2015082887A2 (en) 2015-06-11
EP3076966A2 (en) 2016-10-12
US9801880B2 (en) 2017-10-31
JP2016539138A (ja) 2016-12-15
US20160339021A1 (en) 2016-11-24
JP2020128402A (ja) 2020-08-27

Similar Documents

Publication Publication Date Title
JP6992960B2 (ja) キナーゼ阻害剤の用途
Li et al. Development of anaplastic lymphoma kinase (ALK) small‐molecule inhibitors for cancer therapy
Axelrod et al. Axl as a mediator of cellular growth and survival
Canning et al. Inflammatory signaling by NOD-RIPK2 is inhibited by clinically relevant type II kinase inhibitors
Ueki et al. Increased myeloid cell responses to M-CSF and RANKL cause bone loss and inflammation in SH3BP2 “cherubism” mice
Ren Mechanisms of BCR–ABL in the pathogenesis of chronic myelogenous leukaemia
Frazer et al. Chronic myeloid leukaemia in the 21st century
Ruan et al. Axl is essential for VEGF-A-dependent activation of PI3K/Akt
Shah et al. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency
Tarn et al. Analysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: therapeutic implications through protein modeling
Wicki et al. Acquired resistance to clinical cancer therapy: a twist in physiological signaling
Corbacioglu et al. Newly identified c-KIT receptor tyrosine kinase ITD in childhood AML induces ligand-independent growth and is responsive to a synergistic effect of imatinib and rapamycin
El‐Deeb et al. ROS receptor tyrosine kinase: a new potential target for anticancer drugs
Song et al. ERBB3, IGF1R, and TGFBR2 expression correlate with PDGFR expression in glioblastoma and participate in PDGFR inhibitor resistance of glioblastoma cells
KR20230025941A (ko) 비-erk mapk 경로 억제제-내성 암을 치료하기 위한 방법 및 조성물
Alves et al. IGF1R/IRS1 targeting has cytotoxic activity and inhibits PI3K/AKT/mTOR and MAPK signaling in acute lymphoblastic leukemia cells
Hung et al. SET antagonist enhances the chemosensitivity of non-small cell lung cancer cells by reactivating protein phosphatase 2A
Tang et al. Dual targeting of salt inducible kinases and CSF1R uncouples bone formation and bone resorption
Murugesan et al. Tyrosine kinase inhibitors (TKIs) in lung cancer treatment: a comprehensive analysis
Hu et al. Discovery of highly potent and efficient CBP/p300 degraders with strong in vivo antitumor activity
Choi et al. Elevated dual specificity protein phosphatase 4 in cardiomyopathy caused by lamin A/C gene mutation is primarily ERK1/2-dependent and its depletion improves cardiac function and survival
Tan et al. Inhibition of type 4 cyclic nucleotide phosphodiesterase blocks intracellular TLR signaling in chronic lymphocytic leukemia and normal hematopoietic cells
Kaelin Jr Molecular biology of kidney cancer
JPWO2006137469A1 (ja) 代謝型グルタミン酸受容体活性化剤
EP2443255B1 (en) Csf1r-derived polynucleotides for medical use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171115

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171115

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180725

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180807

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190521

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190814

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191118

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200501

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20200501

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20200519

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200707

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20200714

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20200807

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20200818

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210105

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210413

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20210511

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210806

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210928

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20211005

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20211109

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20211109

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211202

R150 Certificate of patent or registration of utility model

Ref document number: 6992960

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees